ORIC Pharmaceuticals, Inc., a clinical-stage oncology company, announced a private placement of approximately 19.2 million shares of its common stock, offered at $6.50 per share, to institutional and accredited healthcare specialist investors. This sale represents an 18% premium to ORIC's 10-day trailing volume-weighted average price as of May 23, 2025. The financing, expected to close on May 29, 2025, is anticipated to generate gross proceeds of approximately $125 million. The funds will support the development of ORIC's clinical-stage product candidates and research programs, and are projected to sustain operations through the second half of 2027, including the primary endpoint readout from the ORIC-944 Phase 3 trial in prostate cancer. The financing round is led by SR One, with participation from notable investors including Point72, Viking Global Investors, and NEA.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。